Cell Therapeutics Inc. - CTIC

**TGK** · 02-21-2009 06:31 AM

'CTIC' News -- *DJ Cell Therapeutics To Get $6M At Close Of Sale ...

Friday, February 20, 2009 4:07 PM

From:
"StockAlerts@scottrade.com"

Scottrade.com
This email is compliments of Scottrade.com

If you would like to modify or suspend this alert, please login to your Scottrade account and navigate to the "Alerts" page under the "My Account" tab.
News for 'CTIC' - (*DJ Cell Therapeutics To Get $6M At Close Of Sale >CTIC)

(MORE TO FOLLOW) Dow Jones Newswires (201-938-5400)

February 20, 2009 16:06 ET (21:06 GMT)

Copyright (c) 2009 Dow Jones & Company, Inc.- - 04 06 PM EST 02-20-09

Source: DJ Broad Tape

**TGK** · 02-21-2009 06:39 AM

'CTIC' News -- *DJ Cell Therapeutics To Get $6M At Close Of Sale ...

Friday, February 20, 2009 4:07 PM

From:
"StockAlerts@scottrade.com"

Scottrade.com
This email is compliments of Scottrade.com

News for 'CTIC' - (*DJ Cell Therapeutics To Get $6M At Close Of Sale >CTIC)

(MORE TO FOLLOW) Dow Jones Newswires (201-938-5400)

February 20, 2009 16:06 ET (21:06 GMT)

Copyright (c) 2009 Dow Jones & Company, Inc.- - 04 06 PM EST 02-20-09

Source: DJ Broad Tape

**TGK** · 02-21-2009 06:41 AM

'CTIC' News -- *DJ Cell Therapeutics: Zevalin Sale Will Cut Expen...

Friday, February 20, 2009 4:07 PM

From:
"StockAlerts@scottrade.com"

Scottrade.com
This email is compliments of Scottrade.com

News for 'CTIC' - (*DJ Cell Therapeutics: Zevalin Sale Will Cut Expenses By $15M/Yr)

(MORE TO FOLLOW) Dow Jones Newswires (201-938-5400)

February 20, 2009 16:06 ET (21:06 GMT)

Copyright (c) 2009 Dow Jones & Company, Inc.- - 04 06 PM EST 02-20-09

Source: DJ Broad Tape

**TGK** · 02-21-2009 06:47 AM

'CTIC' News -- *DJ Cell Therapeutics Sells Venture Stake To Spect...

Friday, February 20, 2009 4:07 PM

From:
"StockAlerts@scottrade.com"
View contact details

Scottrade.com
This email is compliments of Scottrade.com

News for 'CTIC' - (*DJ Cell Therapeutics Sells Venture Stake To Spectrum For $18M)

(MORE TO FOLLOW) Dow Jones Newswires (201-938-5400)

February 20, 2009 16:06 ET (21:06 GMT)

Copyright (c) 2009 Dow Jones & Company, Inc.- - 04 06 PM EST 02-20-09

Source: DJ Broad Tape

**TGK** · 02-21-2009 06:49 AM

'CTIC' News -- *DJ Cell Therapeutics Sells 50% Stake In Zevalin V...

Friday, February 20, 2009 4:06 PM

From:
"StockAlerts@scottrade.com"

Scottrade.com
This email is compliments of Scottrade.com

News for 'CTIC' - (*DJ Cell Therapeutics Sells 50% Stake In Zevalin Venture >CTIC)

(MORE TO FOLLOW) Dow Jones Newswires (201-938-5400)

February 20, 2009 16:05 ET (21:05 GMT)

Copyright (c) 2009 Dow Jones & Company, Inc.- - 04 05 PM EST 02-20-09

Source: DJ Broad Tape

**TGK** · 02-21-2009 06:52 AM

'CTIC' News -- *DJ Cell Therapeutics Exercises Its Option To Sell...

Friday, February 20, 2009 4:06 PM

From:
"StockAlerts@scottrade.com"

View contact details

Scottrade.com
This email is compliments of Scottrade.com

News for 'CTIC' - (*DJ Cell Therapeutics Exercises Its Option To Sell Interest In Zevalin Joint Venture To Spectrum Pharmaceuticals For $18 M >CTIC)

(MORE TO FOLLOW) Dow Jones Newswires (201-938-5400)

February 20, 2009 16:05 ET (21:05 GMT)

Copyright (c) 2009 Dow Jones & Company, Inc.- - 04 05 PM EST 02-20-09

Source: DJ Broad Tape

**Stock_Analyzer** · 04-06-2009 08:16 AM

CTI Receives the Second Payment of $6.5 million Associated with the Sale of Interest in Zevalin Joint Venture
Monday April 6, 2009, 1:30 am EDT
Buzz up! Print Related:Cell Therapeutics, Inc.
SEATTLE, April 6 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it received $6.5 million from Spectrum Pharmaceuticals, Inc. (Spectrum) in connection with the sale of its 50% interest in the Zevalin joint venture to Spectrum for approximately $16.5 million that closed in March 2009. CTI previously received approximately $6.5 million on March 2, 2009, related to this transaction, and the remaining $3.5 million, subject to adjustments for expenses and revenues, among other things, is to be received on April 15, 2009. CTI sold an initial 50% interest in Zevalin to Spectrum in connection with the establishment of a 50/50 owned joint venture with Spectrum for approximately $15 million in December 2008, bringing total gross funds that will be received from Spectrum for 100% interest in Zevalin to approximately $31.5 million. CTI originally purchased Zevalin from Biogen Idec Inc. in December 2007 for $10 million (plus certain milestone payments, all of which will be the responsibility of Spectrum if or when they come due).

Related Quotes
Symbol Price Change
CTIC 0.39 0.00

{"s" : "ctic","k" : "c10,l10,p20,t10","o" : "","j" : ""} "In this difficult capital market we are pleased to have access to this non-dilutive operating capital as we advance our products through the regulatory process to approval and commercialization," said James A. Bianco, M.D., CEO of Cell Therapeutics. "We will continue to seek product partnerships and other sources of financing to fund our ongoing operations that in addition to our efforts reducing in expenses will ultimately drive shareholder value."

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit Cell Therapeutics (CTI) Cancer Therapies and Cancer Drug Development Home Page - Cell Therapeutics, Inc..

Sign up for email alerts and get RSS feeds at our Web site,

Investors - Cell Therapeutics, Inc. - Email Alerts

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the ongoing development of the Company's products such as pixantrone and OPAXIO include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with such products in particular including, without limitation, the Company's ability to identify and negotiate product partnerships, the Company's ability to raise additional capital to continue to fund its operations, the potential failure of pixantrone to prove safe and effective for treatment of relapsed aggressive NHL as determined by the FDA, other determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, and costs of developing, producing and selling such products and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:
Dan Eramian
T: 206.272.4343
C: 206.854.1200
E: media@ctiseattle.com
CTI Press Room - Resources for the Media - Cell Therapeutics, Inc.

Investors Contact:
Ed Bell
T: 206.282.7100
Lindsey Jesch Logan
T: 206.272.4347
F: 206.272.4434
E: invest@ctiseattle.com
Investors - Cell Therapeutics, Inc. - Investors

**Stock_Analyzer** · 04-10-2009 02:44 PM

If we can hold the .25 to .30 ranges then we may see a secondary bump up here next week.

**Stock_Analyzer** · 04-14-2009 08:06 AM

Cell Therapeutics Initiating Rolling NDA Submission for Pixantrone

Tuesday , April 14, 2009 01:30ET

KNOBIAS: RAiDAR Story

CTI to Request Priority Review

SEATTLE, April 14 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it began a rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for pixantrone to treat relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL). CTI expects to complete the submission this quarter and will request priority review which if granted could lead to an approval decision from the FDA in Q4 2009.

"This is a significant milestone for CTI as we move pixantrone closer to addressing a truly significant unmet medical need for relapsed or refractory aggressive NHL patients," said James A. Bianco, M.D., CEO of CTI. "The commercialization of pixantrone will drive shareholder value as a result of the large market potential for this product. We believe that the recent significant investment in CTI by a single institutional investor reflects a growing interest in CTI and in particular in pixantrone by the investment community. With added financial resources, CTI can advance pixantrone through the NDA review process while we continue our progress on strategic business development opportunities and relationships."

CTI previously announced that its pivotal phase III (PIX 301) EXTEND trial had achieved its primary endpoint with patients randomized to treatment with pixantrone achieving a significantly higher rate of confirmed (CR) and unconfirmed complete remissions (CRu) compared to patients treated with standard chemotherapy (14/70 (20.0%) for pixantrone arm compared to 4/70 (5.7%) for the standard chemotherapy arm, p = 0.02) with no patients in the standard chemotherapy arm achieving a confirmed complete remission. Additionally, progression-free survival (PFS) results from this study show patients treated with pixantrone experienced a statistically significant improvement in median progression-free survival, compared with other single-agent chemotherapeutic agents (4.7 months vs. 2.6 months, p < 0.01, pixantrone vs. standard chemotherapy) based on an intent to treat analysis. Pixantrone treatment also significantly increased the overall response rate (CR/CRu+PR) (26/70 (37.1%) for pixantrone arm compared to 10/70 (14.3%) for the control arm, p = 0.003).

Pixantrone recipients had a low incidence of severe neutropenia complicated by either fever or documented infections, or severe vomiting or diarrhea. Pixantrone patients also experienced a low incidence of hair loss, a very common side effect of other drugs in this class. Overall, the incidence of serious adverse events was similar between pixantrone and the control arm. The pixantrone patients had a higher incidence of leucopenia and neutropenia and numerically more severe cardiac events (5 vs. 2) with only 1 considered related to the study drug by the investigator. Disease progression reported as an adverse event was less frequent in the pixantrone than in the control arm (1.5% vs. 13.4%).

The pixantrone study received Special Protocol Assessment approval from the FDA in 2004, and pixantrone has received fast track designation for this indication. The FDA's fast track programs are intended to expedite the review of drugs that treat serious or life-threatening conditions and demonstrate the potential to address unmet medical needs. The rolling submission process enables companies that have been granted fast track designation to submit sections of the NDA to the FDA as they become available, allowing the review process to begin before the complete dossier has been submitted.

About Pixantrone

Pixantrone (BBR 2778), is a novel major groove binder with an aza-anthracenedione molecular structure that differentiates it from the anthracyclines and other related chemotherapy agents. Anthracyclines are the cornerstone therapeutic for the treatment of lymphoma, leukemia, and breast cancer. Although they are sufficiently effective to be used as first-line (initial) treatment, they cause cumulative heart damage that may result in congestive heart failure many years later. As a result, there is a lifetime limit of anthracycline doses and most patients who previously have been treated with an anthracycline are not able to receive further anthracycline treatment if their disease returns. Pixantrone has been designed to reduce the potential for these severe cardiotoxicities without sacrificing anti-cancer activity. It also can be administered through a peripheral vein rather than a central implanted catheter as required for other drugs in this class.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit Cell Therapeutics (CTI) Cancer Therapies and Cancer Drug Development Home Page - Cell Therapeutics, Inc..

Sign up for email alerts and get RSS feeds at our Web site, Investors - Cell Therapeutics, Inc. - 2009 News Releases

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with pixantrone in particular including the potential failure of pixantrone to prove safe and effective for treatment of relapsed aggressive NHL as determined by the FDA, the possibility that the NDA submission will not be completed in the second quarter of 2009, that priority review is not granted and that a decision by the FDA is not rendered in late 2009, the Company will be able to complete strategic partnerships, the Company's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:
Dan Eramian
T: 206.272.4343
C: 206.854.1200
E: media@ctiseattle.com
CTI Press Room - Resources for the Media - Cell Therapeutics, Inc.

Investors Contact:
Ed Bell
T: 206.282.7100
Lindsey Jesch Logan
T: 206.272.4347
F: 206.272.4434
E: invest@ctiseattle.com
Investors - Cell Therapeutics, Inc. - Investors

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Jack W. Singer, M.D.

https://profnet.prnewswire.com/Subsc....aspx?ei=60728

James A. Bianco, M.D.

https://profnet.prnewswire.com/Subsc....aspx?ei=60729

SOURCE Cell Therapeutics, Inc.

Contacts:

Media
Dan Eramian
206-272-4343
cell
206-854-1200
media@ctiseattle.com

Investors, Ed Bell
206-282-7100
Lindsey Jesch Logan
206-272-4347
fax
206-272-4434
invest@ctiseattle.com

all of Cell Therapeutics, Inc.

Public Companies Associated with this story:
CTIC

Content provided by PR Newswire Copyright � 2009
Content transmitted by Knobias.com Copyright � 2009 Visit Knobias.com

KNOBIAS: RAiDAR Story

ABOUT | PARTNERS | ADVERTISING INFO | CONTACT US | COPYRIGHT | PRIVACY | LEGAL | DISCLAIMER
Copyright � 2009 Knobias.Com, LLC. All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Knobias.Com, LLC, nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Knobias.Com website(s), a user agrees not to redistribute the information found therein. Knobias.Com, LLC is not a registered broker-dealer and does not endorse or recommend any securities listed herein or any services of any brokerage company.

**chuck44l** · 04-18-2009 01:25 PM

CTIC > SEC Filings for CTIC > Form 8-K on 17-Apr-2009 All Recent SEC Filings

17-Apr-2009

Entry into a Material Definitive Agreement, Unregistered Sale of Equity Sec

Item 1.01 Entry into a Material Definitive Agreement
Cell Therapeutics, Inc. (the "Company") entered into an Exchange Agreement dated April 7, 2009 with Milfam I L.P. Pursuant to such Exchange Agreement, on April 7, 2009 the Company issued to Milfam I L.P. 288,517 shares of newly-issued Common Stock of the Company in exchange for 100 shares of outstanding Series A 3% Convertible Preferred Stock and outstanding warrants to purchase 747 shares of Company Common Stock.

In addition, in a separate transaction, the Company entered into an Exchange Agreement dated April 8, 2009 with CD Investment Partners, Ltd. Pursuant to such Exchange Agreement, on April 17, 2009 the Company issued to CD Investment Partners, Ltd. 3,452,493 shares of newly-issued Common Stock of the Company in exchange for 1,000 shares of outstanding Series D 7% Convertible Preferred Stock and outstanding warrants to purchase 19,138 shares of Company Common Stock. (The number of shares issued was derived by a formula, set forth in such Exchange Agreement, based on the average of the volume-weighted average prices of the Company's Common Stock for the three trading days following the Company's public announcement of an issuance of securities pursuant to its Form S-3 shelf registration statement, which resulted in using the trading prices of the Company's Common Stock on April 14, 15 and 16, 2009.)

The description of the terms and conditions of the two Exchange Agreements set forth herein does not purport to be complete and is qualified in its entirety by reference to the full text of the two Exchange Agreements, which are attached hereto as Exhibits 10.1 and 10.2, respectively.

The offer and issuance of the Common Stock pursuant to the two Exchange Agreements were exempted by Section 3(a)(9) of the Securities Act of 1933, as amended (the "Securities Act") from the Securities Act's registration requirement.

Item 3.02 Unregistered Sales of Equity Securities
The information provided in Item 1.01 and 8.01 of this Current Report on Form 8-K is incorporated herein by reference.

Item 8.01 Other Events
On April 1 and 2, 2009, the holders of all 6,702 outstanding shares of the Company's Series F Preferred Stock converted their Series F Preferred Stock into an aggregate of 47,871,425 shares of the Company's Common Stock, pursuant to the terms of the Series F Preferred Stock. The issuance of the Common Stock upon such conversions was exempted by Securities Act Section 3(a)(9) from the Securities Act's registration requirement.

On April 13, 14, 15 and 16, 2009, Cranshire Capital, L.P., the holder of all of the 15,000 outstanding shares of the Company's Series 1 Preferred Stock, converted all shares of such Series 1 Preferred Stock into an aggregate of 50,000,000 shares of the Company's Common Stock, pursuant to the terms of the Series 1 Preferred Stock. The issuance of the Common Stock upon such conversions was exempted by Securities Act Section 3(a)(9) from the Securities Act's registration requirement.

From time to time the Company makes public announcements regarding the number of issued and outstanding shares of its Common Stock. As of the close of business on April 17, 2009, the Company had 433,181,335 shares of Common Stock issued and outstanding.

From time to time the Company makes public announcements regarding the number of issued and outstanding shares of its Preferred Stock. As of the close of business on April 17, 2009, the Company had no shares of any series of the Company's Preferred Stock issued and outstanding.

Item 9.01 Financial Statements and Exhibits
(d) Exhibits

Exhibit No. Description

10.1 Exchange Agreement, dated April 7, 2009, by and between Cell
Therapeutics, Inc. and Milfam I L.P.

10.2 Exchange Agreement, dated April 8, 2009, by and between Cell
Therapeutics, Inc. and CD Investment Partners, Ltd.

A mixture of other popular plays for for the coming week can be found by clicking on the link below ranging all the way from large caps to hot penny stocks.

http://www.stockhideout.com/chucks-s...l-19-09-a.html

Thread: Cell Therapeutics Inc. - CTIC

Thread Tools

Display

News for 'CTIC' - (*DJ Cell Therapeutics To Get $6M At Close Of Sale >CTIC)

News for 'CTIC' - (*DJ Cell Therapeutics To Get $6M At Close Of Sale >CTIC)

News for 'CTIC' - (*DJ Cell Therapeutics: Zevalin Sale Will Cut Expenses By $15M/Yr)

News for 'CTIC' - (*DJ Cell Therapeutics Sells Venture Stake To Spectrum For $18M)

News for 'CTIC' - (*DJ Cell Therapeutics Sells 50% Stake In Zevalin Venture >CTIC)

News for 'CTIC' - (*DJ Cell Therapeutics Exercises Its Option To Sell Interest In Zevalin Joint Ven

Re: Cell Therapeutics Inc. - CTIC

Re: Cell Therapeutics Inc. - CTIC

Re: Cell Therapeutics Inc. - CTIC

Re: Cell Therapeutics Inc. - CTIC

Thread Information

Users Browsing this Thread

Similar Threads

Advanced Cell Technology Inc. - ACTC

Stem Cell Inovations Inc. - SCLL

Bookmarks

Bookmarks

Posting Permissions